Published in Br J Cancer on July 01, 1996
Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol (2002) 2.81
Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol (1997) 2.15
Correlation of IL-8 with induction, progression and metastatic potential of colorectal cancer. World J Gastroenterol (2007) 1.16
Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-ribose) polymerase-1. Oncogene (2006) 1.06
Fine tuning the transcriptional regulation of the CXCL1 chemokine. Prog Nucleic Acid Res Mol Biol (2003) 0.96
Loss of integrin alpha1beta1 ameliorates Kras-induced lung cancer. Cancer Res (2008) 0.94
Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br J Cancer (1998) 0.90
Targeting sphingosine kinase-1 to inhibit melanoma. Pigment Cell Melanoma Res (2012) 0.85
Mapping of potent and specific binding motifs, GLOGEN and GVOGEA, for integrin α1β1 using collagen toolkits II and III. J Biol Chem (2012) 0.84
Expression of SCF splice variants in human melanocytes and melanoma cell lines: potential prognostic implications. Br J Cancer (2000) 0.83
Characterization of a human cell line stably over-expressing the candidate oncogene, dual specificity phosphatase 12. PLoS One (2011) 0.82
Development of five new melanoma low passage cell lines representing the clinical and genetic profile of their tumors of origin. Pigment Cell Melanoma Res (2012) 0.78
The role of Wnt/β-catenin signaling pathway in melanoma epithelial-to-mesenchymal-like switching: evidences from patients-derived cell lines. Oncotarget (2016) 0.77
CC chemokine receptor 10 cell surface presentation in melanocytes is regulated by the novel interaction partner S100A10. Sci Rep (2016) 0.77
Derivate Isocorydine (d-ICD) Suppresses Migration and Invasion of Hepatocellular Carcinoma Cell by Downregulating ITGA1 Expression. Int J Mol Sci (2017) 0.75
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med (1994) 5.67
A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1994) 5.03
Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med (1994) 4.20
Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res (1991) 3.47
Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet (1991) 2.75
Enzymatic control of pigmentation in mammals. FASEB J (1991) 2.47
IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol (1993) 2.44
Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Rev (1986) 2.42
Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res (1994) 2.28
Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line. Int J Cancer (1991) 2.26
Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest (1991) 2.08
A melanocyte-specific gene, Pmel 17, maps near the silver coat color locus on mouse chromosome 10 and is in a syntenic region on human chromosome 12. Proc Natl Acad Sci U S A (1991) 1.97
Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res (1985) 1.85
Growth and invasion of human melanomas in human skin grafted to immunodeficient mice. Am J Pathol (1993) 1.39
Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol (1993) 1.37
Extrapulmonary, tissue-specific metastasis formation in nude mice injected with FEMX-I human melanoma cells. Cancer Res (1988) 1.29
Establishment and characterization of a human melanoma cell line (MV3) which is highly metastatic in nude mice. Int J Cancer (1991) 1.28
Human melanoma: development and progression. Cancer Metastasis Rev (1990) 1.24
Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer (1989) 1.18
Targeted vectors for gene therapy. FASEB J (1995) 1.18
Molecular characterization of a human tyrosinase-related-protein-2 cDNA. Patterns of expression in melanocytic cells. Eur J Biochem (1994) 1.12
Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. J Clin Invest (1993) 1.11
Tumour progression and metastatic behaviour in vivo correlates with integrin expression on melanocytic tumours. J Pathol (1993) 1.08
Emergence of alpha 5 beta 1 fibronectin- and alpha v beta 3 vitronectin-receptor expression in melanocytic tumour progression. Histopathology (1994) 1.04
Role of the alpha 5 beta 1 integrin receptor in the proliferative response of quiescent human melanoma cells to fibronectin. Cancer Res (1992) 0.98
Production and characterization of monoclonal antibodies against the novel neutrophil activating peptide NAP/IL-8. J Immunol (1989) 0.97
Downstream region of the human tyrosinase-related protein gene enhances its promoter activity. Biochem Biophys Res Commun (1992) 0.89
Comparative studies between nude and scid mice on the growth and metastatic behavior of xenografted human tumors. Clin Exp Metastasis (1992) 0.89
Characterization of gene regulatory elements for selective gene expression in human melanoma cells. Biochem Biophys Res Commun (1995) 0.88
Stimulation of angiogenesis as an explanation of Matrigel-enhanced tumorigenicity. Int J Cancer (1994) 0.88
Glycoconjugate profile and CD44 expression in human melanoma cell lines with different metastatic capacity. Int J Cancer (1995) 0.87
Practical spontaneous metastasis model for in vivo therapeutic studies using a human melanoma. Cancer Res (1991) 0.86
Immunogenicity of human melanoma-associated antigens defined by murine monoclonal antibodies in allogeneic and xenogeneic hosts. Cancer Res (1987) 0.82
Expression cloning of the cDNA encoding a melanoma-associated Ag recognized by mAb HMB-45. Identification as melanocyte-specific Pmel 17 cDNA. Lab Invest (1995) 0.82
Alpha v-integrins in human melanoma: gain of alpha v beta 3 and loss of alpha v beta 5 are related to tumor progression in situ but not to metastatic capacity of cell lines in nude mice. Int J Cancer (1995) 0.82
Establishment of a human melanoma cell line lacking p53 expression and spontaneously metastasizing in nude mice. Anticancer Res (1995) 0.81
Tumorigenicity and dissemination of primary and metastatic human melanomas implanted into different sites in athymic nude mice. Invasion Metastasis (1988) 0.80
Lysis of allogeneic and autologous melanoma cells by IL-7-induced lymphokine-activated killer cells. Br J Cancer (1994) 0.78
Accuracy of resistive and pulsatile indices in the diagnosis of graft rejection in renal allografts. Transplant Proc (1994) 0.77
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48
Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin 1 activity. J Immunol (1987) 4.43
European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol (2009) 3.56
Update on the use of ciclosporin in immune-mediated dermatoses. Br J Dermatol (2006) 2.49
Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. Mol Biol Cell (1998) 2.24
Structure determination of a human lymphocyte derived neutrophil activating peptide (LYNAP). Biochem Biophys Res Commun (1988) 2.10
Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res (2000) 2.09
Antitumor benzothiazoles. 3. Synthesis of 2-(4-aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo. J Med Chem (1996) 1.93
C3a and C5a stimulate chemotaxis of human mast cells. Blood (1997) 1.55
EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy (2006) 1.55
Is a single oral dose of ivermectin sufficient in crusted scabies? Int J Dermatol (2001) 1.44
Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. Br J Dermatol (2012) 1.42
Purification and partial biologic characterization of a human lymphocyte-derived peptide with potent neutrophil-stimulating activity. J Immunol (1988) 1.42
Expression and function of adenosine receptors in human dendritic cells. FASEB J (2001) 1.40
Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol (1999) 1.40
[Skin blackish hyperpigmentation in 3 patients]. Hautarzt (2002) 1.38
[Urticaria pigmentosa and mastocytosis]. Dtsch Med Wochenschr (1998) 1.38
Sensitive PCR method for the detection and real-time quantification of human cells in xenotransplantation systems. Br J Cancer (2002) 1.33
European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol (2006) 1.30
EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy (2006) 1.28
The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br J Cancer (1999) 1.22
The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol (2008) 1.18
Inhibition of dendritic cell differentiation by fumaric acid esters. J Invest Dermatol (2001) 1.16
Psoriasis: rationale for targeting interleukin-17. Br J Dermatol (2012) 1.14
Mast cells and their mediators in cutaneous wound healing--active participants or innocent bystanders? Exp Dermatol (1999) 1.13
Acute urticaria: clinical aspects and therapeutic responsiveness. Acta Derm Venereol (1996) 1.10
Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies. Br J Cancer (2009) 1.09
Small vessel vasculitis and relapsing panniculitis in tumour necrosis factor receptor associated periodic syndrome (TRAPS). Ann Rheum Dis (2004) 1.08
Quantification of human cells in NOD/SCID mice by duplex real-time polymerase-chain reaction. Haematologica (2001) 1.08
Miliaria crystallina in an intensive care setting. Clin Exp Dermatol (2004) 1.08
Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J Invest Dermatol (1998) 1.06
Membrane transport proteins associated with drug resistance expressed in human melanoma. Am J Pathol (1995) 1.04
Childhood all blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice. Pediatr Hematol Oncol (2000) 1.04
Keratin 17 gene expression during the murine hair cycle. J Invest Dermatol (1997) 1.03
Topical calcitriol enhances normal hair regrowth but does not prevent chemotherapy-induced alopecia in mice. Cancer Res (1996) 1.02
Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria. J Allergy Clin Immunol (1999) 1.01
A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol (2002) 1.01
Non-adherence and measures to improve adherence in the topical treatment of psoriasis. J Eur Acad Dermatol Venereol (2014) 0.98
Mast cells and vasculature in atopic dermatitis--potential stimulus of neoangiogenesis. Allergy (2005) 0.97
Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol (2000) 0.97
Impact of vaccinations and infectious diseases on the risk of melanoma--evaluation of an EORTC case-control study. Eur J Cancer (2003) 0.97
[Keloids. A fibroproliferative disorder of unknown etiology]. Hautarzt (2002) 0.96
Expression and functional activity of the IL-8 receptor type CXCR1 and CXCR2 on human mast cells. J Immunol (1998) 0.96
Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther (1998) 0.95
Molecular regulation of human IgE synthesis. J Mol Med (Berl) (1997) 0.95
German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res (2007) 0.94
Mastocytosis: recent advances in defining the disease. Br J Dermatol (2001) 0.94
Human skin mast cells rapidly release preformed and newly generated TNF-alpha and IL-8 following stimulation with anti-IgE and other secretagogues. Exp Dermatol (2001) 0.94
Differential expression of angiotensin receptors in human cutaneous wound healing. Br J Dermatol (2005) 0.94
Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis--a multinational cross-sectional study. Arch Dermatol Res (2013) 0.94
Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner. J Invest Dermatol (2001) 0.94
Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage. Dermatology (1996) 0.93
Infections and melanoma risk: results of a multicentre EORTC case-control study. European Organization for Research and Treatment of Cancer. Melanoma Res (1999) 0.93
Increase in granzyme B+ lymphocytes and soluble granzyme B in bronchoalveolar lavage of allergen challenged patients with atopic asthma. Clin Exp Immunol (2004) 0.92
The inflammatory infiltrate in psoriasis. Clin Dermatol (1995) 0.92
Release of stem cell factor from a human keratinocyte line, HaCaT, is increased in differentiating versus proliferating cells. J Invest Dermatol (1996) 0.92
Evaluation of systemic provocation tests in patients with suspected allergic and pseudoallergic drug reactions. Acta Derm Venereol (1999) 0.91
Production of interleukin-6 by human mast cells and basophilic cells. J Invest Dermatol (1996) 0.91
Novel unconventional therapeutic approaches to atopic eczema. Dermatology (2000) 0.91
Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients. Eur J Cancer (2005) 0.91
Loss of tumourigenicity of stably ERbeta-transfected MCF-7 breast cancer cells. Mol Cell Endocrinol (2007) 0.90
Influence of polybutylcyanoacrylate nanoparticles and liposomes on the efficacy and toxicity of the anticancer drug mitoxantrone in murine tumour models. J Microencapsul (1993) 0.90
Retinoic acid inhibits CD40 + interleukin-4-mediated IgE production in vitro. Blood (1998) 0.90
Microscopic morphology of different types of urticaria. Arch Dermatol (1998) 0.90
Identification of two endogenous neutrophil-activating peptides in psoriatic skin and inflammatory cells: C5ades arg and NAP. Dermatologica (1989) 0.90
Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br J Cancer (1998) 0.90
INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model. Invest New Drugs (2009) 0.90
Erythema elevatum diutinum--evidence for disease-dependent leucocyte alterations and response to dapsone. Br J Dermatol (2000) 0.90
Treatment of severe psoriasis with anti-CD25 monoclonal antibodies. Arch Dermatol (2000) 0.90
Altered neutrophil homeostasis in kinin B1 receptor-deficient mice. Biol Chem (2001) 0.90
Genetic susceptibility to keloid disease and transforming growth factor beta 2 polymorphisms. Br J Plast Surg (2002) 0.90
Novel Clostridium perfringens enterotoxin suicide gene therapy for selective treatment of claudin-3- and -4-overexpressing tumors. Gene Ther (2011) 0.89
Allopurinol: a therapeutic alternative for disseminated cutaneous sarcoidosis. Br J Dermatol (1996) 0.89
German S3-guidelines on the treatment of psoriasis vulgaris (short version). Arch Dermatol Res (2012) 0.89
Definition, classification, and routine diagnosis of urticaria: a consensus report. J Investig Dermatol Symp Proc (2001) 0.89
Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology (1996) 0.89
Comparative cytokine gene expression: regulation and release by human mast cells. Immunology (1998) 0.89
Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology (2009) 0.89
Genetic susceptibility to keloid disease: transforming growth factor beta receptor gene polymorphisms are not associated with keloid disease. Exp Dermatol (2004) 0.89
Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel. Int J Oncol (2010) 0.88
The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol (2001) 0.88
Physical properties and pharmacological activity in vitro and in vivo of optimised liposomes prepared from a new cancerostatic alkylphospholipid. Biochim Biophys Acta (1998) 0.87
Detection of intracellular interleukin-8 in human mast cells: flow cytometry as a guide for immunoelectron microscopy. J Histochem Cytochem (1997) 0.87
Laser-induced weal and flare reactions: clinical aspects and pharmacological modulation. Br J Dermatol (2002) 0.87
Hair growth control by immunosuppression. Arch Dermatol Res (1996) 0.87
Human leukaemic (HMC-1) and normal skin mast cells express beta 2-integrins: characterization of beta 2-integrins and ICAM-1 on HMC-1 cells. Scand J Immunol (1997) 0.87
Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions. Acta Derm Venereol (2002) 0.87
The transcription factor profile of human mast cells in comparison with monocytes and granulocytes. Cell Mol Life Sci (2005) 0.87
Mast cell chymase and tryptase during tissue turnover: analysis on in vitro mitogenesis of fibroblasts and keratinocytes and alterations in cutaneous scars. Exp Dermatol (1999) 0.86
Impact of comorbidities on the management of psoriasis. Curr Probl Dermatol (2009) 0.86
Hair cycle-dependent changes in the gene expression and protein content of transforming factor beta 1 and beta 3 in murine skin. Arch Dermatol Res (1997) 0.86
Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo. J Cell Biol (1996) 0.86
Detection of the chemokine RANTES in cytokine-stimulated human dermal fibroblasts. J Invest Dermatol (1995) 0.86
Dimethylfumarate inhibits nuclear binding of nuclear factor kappaB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein beta in activated human T cells. Br J Dermatol (2007) 0.86
Genetic susceptibility to keloid disease: mutation screening of the TGFbeta3 gene. Br J Plast Surg (2005) 0.86